Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial
暂无分享,去创建一个
Kathleen A. Marshall | V. Mahajan | S. Russell | J. Wittes | E. Stone | J. Bennett | J. Haller | O. Elci | E. Sohn | J. F. Wright | D. Chung | K. High | M. Weckmann | L. Raffini | J. Pappas | A. Maguire | Xiaosong Zhu | B. Leroy | F. Simonelli | J. Wellman | Sarah Mccague | A. Drack | W. Pfeifer | Dina Y. Gewaily | Dominique Cross | Taylor Kehoe | L. George | Katie Wachtel | Jean Walshire | Zi-Fan Yu | Amy Tillman | Hannah Reichert | Maria C. Davis | Chris Johnson | F. Hudson | Laura E Dingfield | J. F. Wright | Zi‐Fan Yu | S. Russell | Lindsey A. George
[1] Jean Bennett,et al. Novel mobility test to assess functional vision in patients with inherited retinal dystrophies , 2018, Clinical & experimental ophthalmology.
[2] Jean Bennett,et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial , 2016, The Lancet.
[3] David J. Wilson,et al. Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy. , 2016, Ophthalmology.
[4] Ava K. Bittner,et al. Safety and Proof-of-Concept Study of Oral QLT091001 in Retinitis Pigmentosa Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) , 2015, PloS one.
[5] B. Lorenz,et al. Comprehensive genotyping reveals RPE65 as the most frequently mutated gene in Leber congenital amaurosis in Denmark , 2015, European Journal of Human Genetics.
[6] Kathleen A. Marshall,et al. Plasticity of the human visual system after retinal gene therapy in patients with Leber’s congenital amaurosis , 2015, Science Translational Medicine.
[7] A. J. Roman,et al. Improvement and decline in vision with gene therapy in childhood blindness. , 2015, The New England journal of medicine.
[8] S. E. Barker,et al. Long-term effect of gene therapy on Leber's congenital amaurosis. , 2015, The New England journal of medicine.
[9] A. Auricchio,et al. Vector platforms for gene therapy of inherited retinopathies , 2014, Progress in Retinal and Eye Research.
[10] Gislin Dagnelie,et al. Oral 9-cis retinoid for childhood blindness due to Leber congenital amaurosis caused by RPE65 or LRAT mutations: an open-label phase 1b trial , 2014, The Lancet.
[11] Gislin Dagnelie,et al. A pilot study of an acupuncture protocol to improve visual function in retinitis pigmentosa patients , 2014, Clinical & experimental optometry.
[12] K. High,et al. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. , 2013, Blood.
[13] Paolo Melillo,et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. , 2013, Ophthalmology.
[14] Alexander Sumaroka,et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement , 2013, Proceedings of the National Academy of Sciences.
[15] Jian-xing Ma,et al. RPE65 Is Present in Human Green/Red Cones and Promotes Photopigment Regeneration in an In Vitro Cone Cell Model , 2011, The Journal of Neuroscience.
[16] Michael J. Castle,et al. Dosage Thresholds for AAV2 and AAV8 Photoreceptor Gene Therapy in Monkey , 2011, Science Translational Medicine.
[17] Kathleen A. Marshall,et al. The human visual cortex responds to gene therapy-mediated recovery of retinal function. , 2011, The Journal of clinical investigation.
[18] J. F. Wright,et al. Manufacturing and regulatory strategies for clinical AAV2-hRPE65. , 2010, Current gene therapy.
[19] Jean Bennett,et al. Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[20] Kathleen A. Marshall,et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial , 2009, The Lancet.
[21] D. Birch,et al. Psychophysical assessment of low visual function in patients with retinal degenerative diseases (RDDs) with the Diagnosys full-field stimulus threshold (D-FST) , 2009, Documenta Ophthalmologica.
[22] J. F. Wright,et al. Transient transfection methods for clinical adeno-associated viral vector production. , 2009, Human gene therapy.
[23] W. Hauswirth,et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. , 2008, Human gene therapy.
[24] Kathleen A. Marshall,et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.
[25] Nick Tyler,et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. , 2008, The New England journal of medicine.
[26] J. F. Wright,et al. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[27] W. Hauswirth,et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[28] T Michael Redmond,et al. Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[29] J. F. Wright,et al. Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[30] Ying Chen,et al. Identification of RDH10, an All-trans Retinol Dehydrogenase, in Retinal Muller Cells. , 2004, Investigative ophthalmology & visual science.
[31] T. Aleman,et al. In utero gene therapy rescues vision in a murine model of congenital blindness. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[32] J. Holladay,et al. Visual acuity measurements. , 2004, Journal of cataract and refractive surgery.
[33] Jian-xing Ma,et al. Identification of the RPE65 protein in mammalian cone photoreceptors. , 2002, Investigative ophthalmology & visual science.
[34] Jean Bennett,et al. Gene therapy restores vision in a canine model of childhood blindness , 2001, Nature Genetics.
[35] P. Sieving,et al. Genetics and phenotypes of RPE65 mutations in inherited retinal degeneration. , 2000, Investigative ophthalmology & visual science.
[36] D. Bok,et al. Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle , 1998, Nature Genetics.
[37] A. Fulton,et al. Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[38] A. Hendrickson,et al. Human photoreceptor topography , 1990, The Journal of comparative neurology.
[39] A. D. den Hollander. Omics in Ophthalmology: Advances in Genomics and Precision Medicine for Leber Congenital Amaurosis and Age-Related Macular Degeneration. , 2016, Investigative Ophthalmology and Visual Science.
[40] M. Kono. Cone Health and Retinoids. , 2015, Progress in molecular biology and translational science.
[41] M. Bach,et al. Resolving the clinical acuity categories “hand motion” and “counting fingers” using the Freiburg Visual Acuity Test (FrACT) , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.
[42] A. Wenzel,et al. Lentiviral vectors containing a retinal pigment epithelium specific promoter for leber congenital amaurosis gene therapy. Lentiviral gene therapy for LCA. , 2006, Advances in experimental medicine and biology.